Gene
CDK12
CDK12 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (7), Actionable biomarkers (2), Trial mentions (57), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDK12. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 3 of 8,738 | 0.03% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 4 of 8,597 | 0.05% | not measured | |
| 2023 | 6 of 8,275 | 0.07% | 17 of 11,460 | 0.15% |
| 2022 | 7 of 8,285 | 0.08% | 20 of 13,598 | 0.15% |
| 2021 | 15 of 8,692 | 0.17% | 16 of 15,045 | 0.11% |
| 2020 | 7 of 7,640 | 0.09% | 14 of 14,459 | 0.10% |
| 2019 | 7 of 7,300 | 0.10% | 5 of 12,159 | 0.04% |
| 2018 | 3 of 6,927 | 0.04% | 11 of 11,854 | 0.09% |
| 2017 | 2 of 6,558 | 0.03% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (7)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AmoyDx | Diagnostic provider | Clinical validationAnalytical validation | 1 | December 08, 2025 |
| Horizon | Reagent supplier | Clinical validationAnalytical validation | 1 | December 08, 2025 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | December 08, 2025 |
| ROCHE | Context dependent | Clinical validationAnalytical validation | 1 | December 08, 2025 |
| SensID | Diagnostic provider | Clinical validationAnalytical validation | 1 | December 08, 2025 |
Showing 5 of 7 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDK12 amplification | Parp Inhibitors | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
| CDK12 oncogenic mutation | Parp Inhibitors | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
Trial mentions (57)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03786796 | Trial eligibility (AACT) |
| NCT03432897 | Trial eligibility (AACT) |
| NCT04104893 | Trial eligibility (AACT) |
| NCT07723651 | Trial eligibility (AACT) |
| NCT04985721 | Trial eligibility (AACT) |
Showing 5 of 57 trial mentions.
Target-disease associations (409)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1-Methylhistidine measurement | measurement | GWAS credible sets |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 409 associations.
Vendor sourcing (204)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | CDK12 | View trial NCT03061188 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.4382dupG variant, located in coding exon 14 of the CDK12 gene, results from a duplication of G at nucleotide position 4382, causing a translational fra... | View ClinVar record SCV002628741.2 |
| Antengene Discovery Limited | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | to be eligible to enroll in this study: 1. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling, and a... | View trial NCT05338346 |
| Antengene Discovery Limited | Trial sponsor | Mentioned in trial textTrial free-text mention | CDK12 | View trial NCT05338346 |
Showing 5 of 204 sourcing records.
Trial-cited literature (104)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study. | JCO precision oncology | 2025 | 3 |
| First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Nature medicine | 2024 | 130 |
| Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | 68 |
| A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors. | The oncologist | 2024 | 20 |
| Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer. | European urology oncology | 2024 | 7 |
Showing 5 of 104 papers.
Protein variant mentions (7)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.I1131V | 1 | 2015 | PMID 25741868 |
| p.L996F | 1 | 2011 | PMID 21720365 |
| p.P1275L | 1 | 2015 | PMID 25741868 |
| p.R1242* | 1 | 2016 | PMID 27602761 |
| p.R882L | 1 | 2011 | PMID 21720365 |
Showing 5 of 7 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.L996F | TCGA-OV | Not Reported; Cystic, Mucinous and Serous Neoplasms; Ovary; Retroperitoneum and peritoneum | 1 | 603 | 0.17% | 0.03% to 0.93% |
| p.R882L | TCGA-OV | Not Reported; Cystic, Mucinous and Serous Neoplasms; Ovary; Retroperitoneum and peritoneum | 1 | 603 | 0.17% | 0.03% to 0.93% |
Literature-extracted relations (9)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Ovarian Neoplasms | Disease | associate |
A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN). | 2022 |
| Colorectal Neoplasms | Disease | associate |
Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. | 2022 |
| Prostatic Neoplasms, Castration-Resistant | Disease | associate |
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. | 2022 |
| Prostatic Neoplasms | Disease | associate |
Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability. | 2022 |
| Neoplasms | Disease | associate |
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. | 2019 |
Showing 5 of 9 relation assertions.
Organizations publishing (203)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 12 | 2014 to 2024 |
| Université Paris-Saclay | Academic | 9 | 2020 to 2024 |
| Dana-Farber Cancer Institute | Other | 8 | 2015 to 2023 |
| Government of the United States of America | Government | 8 | 2013 to 2023 |
| University of Washington | Academic | 7 | 2015 to 2023 |
Showing 5 of 203 organizations.
Where CDK12 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- measurement
- nervous system disease
- phenotype
- reproductive system or breast disease
- urinary system disease
383 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.